News

myMatrixx President, Mike Cirillo, recently sat down with national charity Kids’ Chance of America (KCOA) to share his thoughts on the importance of their mission and the actions he and myMatrixx take to support it.

myMatrixx, presents a new panel on the increasing use of psychotropic drugs among injured workers at WCI Virtual Reboot Seminar.

One of the top priorities for successfully mitigating COVID-19 is the development of an effective yet safe vaccine. Currently there are more than 100 potential vaccines in development, with projections for commercial availability a year or more away. To provide the latest information, myMatrixx is...

As transparent pricing continues to be a key topic for workers’ compensation PBMs, Mike Cirillo, President of myMatrixx, recently sat down with Risk & Insurance magazine to discuss common myths that are out there in the marketplace.

Gilead Sciences received full U.S. Food and Drug Administration (FDA) approval on Oct. 22, 2020, for Veklury® (remdesivir) injection. Remdesivir is to be marketed under brand name Veklury.

Mental health is an easy-to-overlook aspect of the ongoing COVID-19 pandemic, but there is evidence that it is having an effect on Americans. Ahead of an upcoming virtual panel for the Workers’ Compensation Institute (WCI), myMatrixx Chief Clinical Officer, Phil Walls, shared his thoughts on this growing trend for the organization’s weekly news update.

As the overall population continues to age, so too does the workforce. The implications of this from a worker safety standpoint and for treating workplace injuries is the subject of a myMatrixx White Paper that was covered in an Expert’s View feature on industry publication WorkersCompensation.com....

On September 16th, myMatrixx parent company Cigna announced the launch of a new brand for its growing portfolio of high-performing health services. Evernorth was created to accelerate delivery of flexible solutions to meet the diverse needs of health plans, employers and government organizations....

Qdolo ™ (tramadol – Athena Bioscience) oral solution, 5mg/mL was approved on Sept. 1, 2020, by the U.S. Food and Drug Administration (FDA). A C-IV controlled substance, it is indicated for treating adults who have severe pain that requires an opioid, but that does not respond to other treatments....

In a new Work Comp Wire article, Chief Sales Officer David Dubrof discusses how strong pharmacy network relationships and clinical oversight are more important for a long-term claims management strategy. Newly appointed myMatrixx Chief Sales Officer, David Dubrof, was featured in the most recent...